Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
oNet Registry Update March 2005<br />
dverse Events/Side Effects (AE) and Vascular Access Problems (VAP (VAP<br />
<strong>Age</strong> <strong>Related</strong> Frequencies<br />
Class I events<br />
All indications<br />
%<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
n = 3507 protocols<br />
0-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100<br />
Years<br />
Adverse events / side effects Vascular access problems<br />
Class II events<br />
All indications<br />
%<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
n = 3507 protocols<br />
0-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100<br />
Years<br />
21% of <strong>AMD</strong><br />
patients were<br />
≥ 80 years<br />
Adverse events / side effects Vascular access problems
Change language